Abstract
Summary
The North America PCR-based infectious diseases market is expected to reach USD 2,466,991.74 thousand by 2031 from USD 1,437,378.74 thousand in 2023, growing with a CAGR of 7.2% in the forecast period of 2024 to 2031.
Market Segmentation
North America PCR-based Infectious Diseases Market, By Test Type (Tuberculosis PCR Test, Hepatitis PCR Test, Human Immunodeficiency Virus (HIV) PCR Test, Influenza PCR Test, Human Papillomavirus (HPV) PCR Test, Gonorrhea PCT Test, Salmonellosis PCR Test, Rotavirus PCR Test, Bordetella PCR Test, H. Pylori PCR Test, Norovirus PCR Test, SARS (COVID-19) PCR Test, Enterococcus PCR Test, Chlamydia Trachomatis Genital PCR Test, C. Difficile (Clostridium Difficile) PCR Test, Carbapenem-Resistant Enterobacteriaceae (CRE) PCR Test, Mycoplasma Genitalium (MG) PCR Test, Methicillin-Resistant Staphylococcus Aureus (MRSA) PCR Test, and Other PCR Test), Infection (Viral Infection, Respiratory Tract Infection, Sexually Transmitted Infection, Hospital Acquired Infections, and Other Infections), Pathogen (Viral, Bacterial, Fungal, Protozoa, and Others), PCR Technology (RT PCR, Multiplex PCR, and Others), Patient Type (Geriatric, Pediatric, and Adults), Testing (Laboratory Based Testing and Point of Care Testing), End User (Diagnostic Centers, Hospital, Academic and Research Institutes, Community Health Centers, Clinics, Home Healthcare, and Others), Country (U.S., Canada, and Mexico) – Industry Trends and Forecast to 2031
Overview of North America PCR-based Infectious Diseases Market Dynamics
Driver
• Increasing PCR-based research activities
Restraint
• High cost of PCR test services
Opportunity
• Disease surveillance for early detection and monitoring of infectious diseases
Market Players
Some of the major market players operating in the North America PCR-based infectious diseases market are:
• DNA Labs India
• DrSafeHands
• Ganesh Diagnostic & Imaging Centre Pvt. Ltd.
• Max Lab
• MicroGen Diagnostics
• pathlab
• The Washington Travel Clinic
• Clarewell Clinics
• AZOVA
• One Life Home Health Care Center
• LalPathLabs
Table of Contents
1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 OVERVIEW OF NORTH AMERICA PCR-BASED INFECTIOUS DISEASES MARKET 17
1.4 CURRENCY AND PRICING 18
1.5 LIMITATIONS 19
1.6 MARKETS COVERED 19
2 MARKET SEGMENTATION 22
2.1 MARKETS COVERED 22
2.2 GEOGRAPHICAL SCOPE 23
2.3 YEARS CONSIDERED FOR THE STUDY 24
2.4 DBMR TRIPOD DATA VALIDATION MODEL 25
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 28
2.6 MULTIVARIATE MODELLING 29
2.7 MARKET APPLICATION COVERAGE GRID 30
2.8 TEST TYPE LIFELINE CURVE 31
2.9 DBMR MARKET POSITION GRID 32
2.10 VENDOR SHARE ANALYSIS 33
2.11 SECONDARY SOURCES 34
2.12 ASSUMPTIONS 34
3 EXECUTIVE SUMMARY 35
4 PREMIUM INSIGHTS 38
4.1 PESTEL ANALYSIS 39
4.2 PORTER’S FIVE FORCES 40
5 MARKET OVERVIEW 41
5.1 DRIVERS 43
5.1.1 INCREASING PCR-BASED RESEARCH ACTIVITIES 43
5.1.2 RISING CASES OF INFECTIOUS DISEASES 43
5.1.3 GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS 44
5.2 RESTRAINTS 45
5.2.1 HIGH COST OF PCR TEST SERVICES 45
5.2.2 SHORTAGE OF SKILLED LABORATORY TECHNICIANS 46
5.3 OPPORTUNITIES 47
5.3.1 DISEASE SURVEILLANCE FOR EARLY DETECTION AND MONITORING OF INFECTIOUS DISEASES 47
5.3.2 RISING INNOVATIONS IN PCR TECHNOLOGY 47
5.3.3 PERSONALIZED PCR-BASED STRATEGIES FOR TARGETED AND EFFECTIVE INTERVENTIONS 48
5.4 CHALLENGES 49
5.4.1 DATA SECURITY AND PRIVACY CONCERNS 49
5.4.2 COMPLEXITY AND TECHNICAL EXPERTISE 49
6 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE 51
6.1 OVERVIEW 52
6.2 TUBERCULOSIS PCR TEST 58
6.3 HEPATITIS PCR TEST 58
6.3.1 HEPATITIS C PCR TEST 59
6.3.2 HEPATITIS B PCR TEST 59
6.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST 60
6.5 INFLUENZA PCR TEST 60
6.6 HUMAN PAPILLOMAVIRUS (HPV) PCR TEST 61
6.7 CHLAMYDIA TRACHOMATIS GENITAL PCR TEST 61
6.8 GONORRHEA PCR TEST 62
6.9 SALMONELLOSIS PCR TEST 62
6.10 ROTAVIRUS PCR TEST 63
6.11 BORDETELLA PCR TEST 63
6.12 H. PYLORI PCR TEST 64
6.13 SARS (COVID-19) PCR TEST 64
6.14 NOROVIRUS PCR TEST 65
6.15 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST 65
6.16 CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST 66
6.17 ENTEROCOCCUS PCR TEST 66
6.18 MYCOPLASMA GENITALIUM (MG) PCR TEST 67
6.19 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST 67
6.20 OTHERS PCR TEST 68
7 NORTH AMERICA PCR-BASED INFECTIOUS DIISEASES MARKET, BY INFECTION 69
7.1 OVERVIEW 70
7.2 VIRAL INFECTION 73
7.2.1 SARS (COVID-19) INFECTION 73
7.2.2 ROTAVIRUS INFECTION 73
7.2.3 NOROVIRUS INFECTION 73
7.2.4 OTHERS 74
7.3 RESPIRATORY TRACT INFECTION 74
7.3.1 INFLUENZA 74
7.3.2 TUBERCULOSIS 74
7.3.3 BORDETELLA 75
7.4 SEXUALLY TRANSMITTED INFECTION 75
7.4.1 CHLAMYDIA TRACHOMATIS GENITAL INFECTION 76
7.4.2 GONORRHEA 76
7.4.3 HEAPTITIS 76
7.4.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 76
7.4.5 HUMAN PAPILLOMAVIRUS (HPV) 76
7.4.6 MYCOPLASMA GENITALIUM (MG) 76
7.4.7 OTHERS 76
7.5 HOSPITAL ACQUIRED INFECTIONS 77
7.5.1 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) 77
7.5.2 CARBAPENEM- RESISTANT ENTEROBACTERIACEAE (CRE) 77
7.5.3 METHICILIN- RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 78
7.5.4 OTHERS 78
7.6 OTHER INFECTIONS 78
7.6.1 SALMONELLOSIS 78
7.6.2 H. PYLORI 79
7.6.3 ENTEROCOCCUS INFECTIONS 79
7.6.4 OTHERS 79
8 NORTH AMERICA PCR-BASED INFECTIOUS DIISEASES MARKET, BY PATHOGEN 80
8.1 OVERVIEW 81
8.2 VIRAL 84
8.3 BACTERIAL 84
8.4 FUNGAL 85
8.5 PROTOZOA 85
8.6 OTHERS 86
9 NORTH AMERICA PCR-BASED INFECTIOUS DIISEASES MARKET, BY PCR TECHNOLOGY 87
9.1 OVERVIEW 88
9.2 RT PCR 91
9.3 MULTIPLEX PCR 91
9.4 OTHERS 92
10 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE 93
10.1 OVERVIEW 94
10.2 GERIATRIC 97
10.3 PEDIATRIC 97
10.4 ADULTS 98
11 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING 99
11.1 OVERVIEW 100
11.2 LABORATORY BASED TESTING 103
11.3 POINT OF CARE TESTING 103
12 NORTH AMERICA PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER 104
12.1 OVERVIEW 105
12.2 DIAGNOSTIC CENTERS 108
12.3 HOSPITAL 108
12.4 CLINICS 109
12.5 COMMUNITY HEALTH CENTERS 109
12.6 ACADEMIC AND RESEARCH INSTITUTES 110
12.7 HOME HEALTHCARE 110
12.8 OTHERS 111
13 NORTH AMERICA PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION 112
13.1 NORTH AMERICA 115
13.1.1 U.S 124
13.1.2 CANADA 132
13.1.3 MEXICO 140
14 NORTH AMERICA PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY LANDSCAPE 148
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 148
15 SWOT ANALYSIS 149
16 COMPANY PROFILE 150
16.1 MICROGEN DIAGNOSTICS 150
16.1.1 COMPANY SNAPSHOT 150
16.1.2 SERVICE PORTFOLIO 150
16.1.3 RECENT DEVELOPMENTS 151
16.2 MAX LAB 152
16.2.1 COMPANY SNAPSHOT 152
16.2.2 SERVICE PORTFOLIO 152
16.3 DNA LABS INDIA 154
16.3.1 COMPANY SNAPSHOT 154
16.3.2 SERVICE PORTFOLIO 154
16.3.3 RECENT DEVELOPMENT 155
16.4 GANESH DIAGNOSTIC & IMAGING CENTRE PVT. LTD 156
16.4.1 COMPANY SNAPSHOT 156
16.4.2 SERVICE PORTFOLIO 156
16.4.3 RECENT DEVELOPMENT 157
16.5 LALPATHLABS 158
16.5.1 COMPANY SNAPSHOT 158
16.5.2 REVENUE ANALYSIS 158
16.5.3 PRODUCT PORTFOLIO 159
16.5.4 RECENT DEVELOPMENTS 159
16.6 AZOVA 160
16.6.1 COMPANY SNAPSHOT 160
16.6.2 PRODUCT PORTFOLIO 160
16.6.3 RECENT DEVELOPMENTS 160
16.7 CLAREWELL CLINICS 161
16.7.1 COMPANY SNAPSHOT 161
16.7.2 PRODUCT DESCRIPTION 161
16.7.3 RECENT DEVELOPMENTS 161
16.8 DRSAFEHANDS 162
16.8.1 COMPANY SNAPSHOT 162
16.8.2 SERVICE PORTFOLIO 162
16.8.3 RECENT DEVELOPMENT 162
16.9 ONE LIFE HOME HEALTH CARE CENTER 163
16.9.1 COMPANY SNAPSHOT 163
16.9.2 PRODUCT DESCRIPTION 163
16.9.3 RECENT DEVELOPMENTS 163
16.10 PATHLAB 164
16.10.1 COMPANY SNAPSHOT 164
16.10.2 SERVICE PORTFOLIO 164
16.10.3 RECENT DEVELOPMENT 164
16.11 THE WASHINGTON TRAVEL CLINIC 165
16.11.1 COMPANY SNAPSHOT 165
16.11.2 SERVICE PORTFOLIO 165
16.11.3 RECENT DEVELOPMENT 166
17 QUESTIONNAIRE 167
18 RELATED REPORTS 171